Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 7/2022

12-11-2021 | Gastric Cancer | Original Article

Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer

Authors: Yang Shen, Xiao-long Li, Yu-xian Li, Zhi-guo Shan, Yong-liang Zhao, Ping Cheng, Zhuo Zhao, Jin-yu Zhang, Weisan Chen, Yuan Zhuang, Dai-yuan Ma, Quan-ming Zou, Yuan Qiu, Liu-sheng Peng

Published in: Cancer Immunology, Immunotherapy | Issue 7/2022

Login to get access

Abstract

CD8+CD103+ tissue-resident memory T cells (TRMs) are involved in tumor immune response and linked to favorable clinical outcome in human cancer. However, the distribution, phenotype, functional properties and clinical relevance of these cells in gastric cancer (GC) remain elusive. Here, our data show that, in comparison to non-tumor tissues, the percentages of CD8+CD103+ TRMs in tumors are significantly decreased. Most tumor-infiltrating CD8+CD103+ TRMs are CD45RACCR7 effector-memory cells with higher PD-1 and 4-1BB expression than those from non-tumor tissues. Further, tumor-infiltrating CD8+CD103+ TRMs show impaired cytolytic capacity due to decreased granzyme B and perforin expression. Moreover, ex vivo PD-1 blockade could restore the cytolytic capacity of tumor-infiltrating CD8+CD103+ TRMs, and such anti-PD-1-mediated reinvigoration of CD8+CD103+ TRMs could be further enhanced by 4-1BB co-stimulation. Finally, lower levels of Tumor-infiltrating CD8+CD103+ TRMs are positively correlated with GC progression and poor patients’ survival. Our data suggest that restoring CD8+CD103+ TRM function by combining PD-1 blockade and 4-1BB co-stimulation may be a promising strategy for treating GC.
Appendix
Available only for authorised users
Literature
Metadata
Title
Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer
Authors
Yang Shen
Xiao-long Li
Yu-xian Li
Zhi-guo Shan
Yong-liang Zhao
Ping Cheng
Zhuo Zhao
Jin-yu Zhang
Weisan Chen
Yuan Zhuang
Dai-yuan Ma
Quan-ming Zou
Yuan Qiu
Liu-sheng Peng
Publication date
12-11-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 7/2022
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-021-03105-0

Other articles of this Issue 7/2022

Cancer Immunology, Immunotherapy 7/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine